{
    "root": "31542b5f-0801-2bea-e063-6294a90a1448",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "BUPROPION HYDROCHLORIDE",
    "value": "20250327",
    "ingredients": [
        {
            "name": "POVIDONE K90",
            "code": "RDH86HJV5Z",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14478"
        },
        {
            "name": "CYSTEINE HYDROCHLORIDE",
            "code": "ZT934N0X4W",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15356"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "GLYCERYL DIBEHENATE",
            "code": "R8WTH25YS2",
            "drugbank_id": "https://go.drugbank.com/drugs/DB13038"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "ETHYLCELLULOSES",
            "code": "7Z8S9VYZ4B",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11228"
        },
        {
            "name": "POLYETHYLENE GLYCOL 1450",
            "code": "OJ4Z5Z32L4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "HYDRATED SILICA",
            "code": "Y6O7T4G8P9",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_64393"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_168426"
        },
        {
            "name": "METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A",
            "code": "NX76LV5T8J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25219"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "BUPROPION HYDROCHLORIDE",
            "code": "ZG7E5POY8O",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3220"
        }
    ],
    "indications": {
        "text": "bupropion hydrochloride extended-release tablets ( xl ) aminoketone antidepressant , indicated : treatment major depressive disorder ( mdd ) ( 1.1 ) prevention seasonal affective disorder ( sad ) ( 1.2 )",
        "doid_entities": [
            {
                "text": "major depressive disorder (DOID:1470)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1470"
            },
            {
                "text": "depressive disorder (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            },
            {
                "text": "seasonal affective disorder (DOID:0060167)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060167"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "general increase dose gradually reduce seizure risk . ( 2.1 , 5.3 ) periodically reassess dose need maintenance treatment . ( 2.2 ) major depressive disorder starting dose : 150 mg daily . usual target dose : 300 mg daily ( 2.2 ) 4 days , may increase dose 300 mg daily . ( 2.2 ) seasonal affective disorder initiate treatment autumn prior onset seasonal depressive symptoms . ( 2.3 ) starting dose : 150 mg daily . usual target dose : 300 mg daily . ( 2.3 ) one week , may increase dose 300 mg daily . ( 2.3 ) continue treatment winter season . ( 2.3 ) hepatic impairment moderate severe hepatic impairment : 150 mg every day ( 2.6 ) mild hepatic impairment : consider reducing dose and/or frequency dosing . ( 2.6 , 8.7 ) renal impairment consider reducing dose and/or frequency dosing . ( 2.7 , 8.6 )",
        "doid_entities": [
            {
                "text": "major depressive disorder (DOID:1470)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1470"
            },
            {
                "text": "depressive disorder (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            },
            {
                "text": "seasonal affective disorder (DOID:0060167)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060167"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe hepatic impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "bupropion hydrochloride extended-release tablets , usp ( xl ) supplied : 150 mg , creamy-white pale yellow , round tablets printed \u201c gs1 \u201d one side plain side ndc : 70518-2458-00 ndc : 70518-2458-01 ndc : 70518-2458-02 ndc : 70518-2458-03 ndc : 70518-2458-04 ndc : 70518-2458-05 ndc : 70518-2458-06 ndc : 70518-2458-07 packaging : 90 1 bottle plastic packaging : 360 1 bottle plastic packaging : 30 1 bottle plastic packaging : 60 1 bottle plastic packaging : 30 1 box packaging : 1 1 pouch packaging : 30 1 bottle plastic packaging : 30 1 blister pack store 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . preserve well-closed containers . protect light . bupropion hydrochloride extended-release tablets , usp ( xl ) may odor . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "bupropion hydrochloride extended-release tablets ( xl ) contraindicated patients seizure disorder . bupropion hydrochloride extended-release tablets ( xl ) contraindicated patients current prior diagnosis bulimia anorexia nervosa higher incidence seizures observed patients treated bupropion hydrochloride extended-release tablets ( xl ) [ ( 5.3 ) ] . bupropion hydrochloride extended-release tablets ( xl ) contraindicated patients undergoing abrupt discontinuation alcohol , benzodiazepines , barbiturates , antiepileptic drugs [ ( 5.3 ) ( 7.3 ) ] . maois ( intended treat psychiatric disorders ) concomitantly bupropion hydrochloride extended-release tablets ( xl ) within 14 days discontinuing treatment bupropion hydrochloride extended-release tablets ( xl ) contraindicated . increased risk hypertensive bupropion hydrochloride extended-release tablets ( xl ) used concomitantly maois . bupropion hydrochloride extended-release tablets ( xl ) within 14 days discontinuing treatment maoi also contraindicated . starting bupropion hydrochloride extended-release tablets ( xl ) patient treated reversible maois linezolid intravenous methylene blue contraindicated [ ( 2.9 ) , ( 5.4 ) ( 7.6 ) ] . bupropion hydrochloride extended-release tablets ( xl ) contraindicated patients known hypersensitivity bupropion ingredients bupropion hydrochloride extended-release tablets ( xl ) . anaphylactoid/anaphylactic stevens-johnson syndrome reported [ ( 5.8 ) ] .",
    "indications_original": "Bupropion hydrochloride extended-release tablets (XL) are an aminoketone antidepressant, indicated for: treatment of major depressive disorder (MDD) ( 1.1 ) prevention of seasonal affective disorder (SAD) ( 1.2 )",
    "contraindications_original": "General Increase dose gradually to reduce seizure risk. ( 2.1 , 5.3 ) Periodically reassess the dose and need for maintenance treatment. ( 2.2 ) Major Depressive Disorder Starting dose: 150 mg once daily. Usual target dose: 300 mg once daily ( 2.2 ) After 4 days, may increase the dose to 300 mg once daily. ( 2.2 ) Seasonal Affective Disorder Initiate treatment in the autumn prior to onset of seasonal depressive symptoms. ( 2.3 ) Starting dose: 150 mg once daily. Usual target dose: 300 mg once daily. ( 2.3 ) After one week, may increase the dose to 300 mg once daily. ( 2.3 ) Continue treatment through the winter season. ( 2.3 ) Hepatic Impairment Moderate to severe hepatic impairment: 150 mg every other day ( 2.6 ) Mild hepatic impairment: Consider reducing the dose and/or frequency of dosing. ( 2.6 , 8.7 ) Renal Impairment Consider reducing the dose and/or frequency of dosing. ( 2.7 , 8.6 )",
    "warningsAndPrecautions_original": "Bupropion hydrochloride extended-release tablets, USP (XL) are supplied as:\n                  150 mg, creamy-white to pale yellow, round tablets printed with \u201cGS1\u201d on one side and plain on the other side\n                  \n                  NDC: 70518-2458-00\n                  NDC: 70518-2458-01\n                  NDC: 70518-2458-02\n                  NDC: 70518-2458-03\n                  NDC: 70518-2458-04\n                  NDC: 70518-2458-05\n                  NDC: 70518-2458-06\n                  NDC: 70518-2458-07\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  PACKAGING: 360 in 1 BOTTLE PLASTIC\n                  PACKAGING: 30 in 1 BOTTLE PLASTIC\n                  PACKAGING: 60 in 1 BOTTLE PLASTIC\n                  PACKAGING: 30 in 1 BOX\n                  PACKAGING: 1 in 1 POUCH\n                  PACKAGING: 30 in 1 BOTTLE PLASTIC\n                  PACKAGING: 30 in 1 BLISTER PACK \n                  \n                  \n                  Store at 25\u00b0C (77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature].Preserve in well-closed containers. Protect from light.\n                  Bupropion hydrochloride extended-release tablets, USP (XL) may have an odor.\n                  \n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with seizure disorder.\n                     Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients treated with bupropion hydrochloride extended-release tablets (XL)\n  \n   [see\n   \n    Warnings and Precautions (5.3)].\n  \n   \n                     \n                     Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs\n  \n   [see\n   \n    Warnings and Precautions (5.3)and\n   \n    Drug Interactions (7.3)].\n  \n   \n                     \n                     The use of MAOIs (intended to treat psychiatric disorders) concomitantly with bupropion hydrochloride extended-release tablets (XL) or within 14 days of discontinuing treatment with bupropion hydrochloride extended-release tablets (XL) is contraindicated. There is an increased risk of hypertensive reactions when bupropion hydrochloride extended-release tablets (XL) are used concomitantly with MAOIs. The use of bupropion hydrochloride extended-release tablets (XL) within 14 days of discontinuing treatment with an MAOI is also contraindicated. Starting bupropion hydrochloride extended-release tablets (XL) in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is contraindicated\n  \n   [see\n   \n    Dosage and Administration (2.9)\n                        ,\n  \n   \n                           Warnings and Precautions (5.4)\n                        and\n  \n   \n                           Drug Interactions (7.6)].\n  \n   \n                     \n                     Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with known hypersensitivity to bupropion or other ingredients of bupropion hydrochloride extended-release tablets (XL). Anaphylactoid/anaphylactic reactions and Stevens-Johnson Syndrome have been reported\n  \n   [see\n   \n    Warnings and Precautions (5.8)].",
    "drug": [
        {
            "name": "BUPROPION HYDROCHLORIDE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3220"
        }
    ]
}